Pharmaceutical

Galecto terminates development for its lead candidate

The Phase IIb trial in idiopathic pulmonary fibrosis for GB0139 did not meet its endpoint, leading Galecto to abandon development.

Aug 16, 2023 - 20:00
Galecto terminates development for its lead candidate
The Phase IIb trial in idiopathic pulmonary fibrosis for GB0139 did not meet its endpoint, leading Galecto to abandon development.
Read the original article

Tags:

Previous Article

Amicus gears up to launch Pompe disease combination therapy in the UK

Next Article

Signal: Illumina under investigation by SEC over $8bn Grail acquisition

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Resilience secures funds to enhance production of essential medicine components

Resilience secures funds to enhance production of essen...

Oct 6, 2024

Vertex secures CHMP nod for Casgevy approval in Europe

Vertex secures CHMP nod for Casgevy approval in Europe

Dec 18, 2023

Novavax is on thin ice, and the latest update isn’t exactly encouraging

Novavax is on thin ice, and the latest update isn’t exa...

Feb 1, 2024